There is a catch. If the private equity firms can boost sales of bluebird’s three gene therapies to $600 million—over any ...

Teva Pharmaceuticals and Alvotech said on Friday they have launched a biosimilar to Johnson & Johnson's autoimmune drug ...

The Make America Healthy Again movement had a negative impact on pharmaceutical innovation and the corporations responsible for it.

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $94.25, a high estimate of $126.00, and a low estimate of $70.00. This current ...

What Happened? Shares of biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) jumped 9.6% in the pre-market session after ...

BioMarin exceeded Q4 earnings expectations, raised 2025 guidance, and projected strong Voxzogo growth. Analysts increased price targets following the results.

When Cathy Tie started Locke Bio, a Culver City-based digital health startup, she had spent years as a venture capitalist seeing a trend in the digital ...